Intercept pharmaceuticals inc.

MORRISTOWN, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced its financial results for the quarter ended on June 30, 2023.For more information about Intercept, please contact: Lisa DeFrancesco +1-646-565-4833 [email protected] Christopher Frates +1-646-757-2371 [email protected]. Source: Intercept Pharmaceuticals, Inc.Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept Pharmaceuticals Inc (NASDAQ:ICPT) announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic ...Jun 22, 2023 · MORRISTOWN, N.J., June 22, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter ...

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in …

MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...

The latest closing stock price for Intercept Pharmaceuticals, Inc. on November 07, 2023 is 19.00. The all-time high Intercept Pharmaceuticals, Inc. closing stock price was 462.26 on March 14, 2014. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide. Historical daily share price chart and data ...Additional Phase 2 trial of the OCA-bezafibrate combination remains ongoing in Europe. MORRISTOWN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral …Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.Follow. NEW YORK, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...

0.36%. $97.68B. ICPT | Complete Intercept Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Jun 22, 2023 · Intercept Pharmaceuticals, Inc. June 22, 2023 at 5:45 PM · 3 min read Company to discontinue all NASH-related investment and restructure the Company’s operations to strengthen its focus on rare ... Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.42. The biopharmaceutical company had revenue of $83.70 million for the quarter, compared to …Subject: Intercept Pharmaceuticals, Inc. – Tender Offer Option Symbol: ICPT Date: 11/07/2023 Intercept Pharmaceuticals, Inc. (ICPT) is the subject of an Offer to Purchase (The “Offer”), as described below: Purchaser:Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma S.p.A.We are hosting our first quarter 2022 financial results conference call and webcast on May 6, 2022, at 8:30 a.m. ET. The conference call will be available on the investor page of our website at ...Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...Company profile page for Intercept Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact informationMORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ...

New data on INT-787, Intercept’s next generation FXR agonist, to be featured in two posters. MORRISTOWN, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a ...BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc. Following the completion …Intercept employees are collaborative, passionate and innovative. We strive for excellence every day because we recognize the responsibility of pioneering for patients in need of therapies. Our employees are enthusiastic and hard-working individuals who embody our values of collaboration, integrity, excellence, innovation, passion and patient-centricity. We recognize that developing new ...Prescription medications are a vital element of healthcare for many people in the United States. While it’s not completely clear how pharmaceutical companies determine pricing for many drugs, some of the most expensive medications and treat...MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted Intercept’s New Drug ...Nareg Sagherian, Executive Director, Global Investor Relations. [email protected]. For media: Karen Preble, Executive Director, Global Corporate Communications. media@interceptpharma ...The Investor Relations website contains information about Intercept Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.

Reprints. Adobe. I ntercept Pharmaceuticals, a firm whose treatment for a prevalent liver disease once made it the hottest stock in biotech, said Tuesday it would sell the company for less than $1 ...

Learn more about ongoing Intercept-sponsored clinical trials below. Primary biliary cholangitis (PBC) Intercept has two ongoing Phase 2 studies, 747-213 and 747-214, that are designed to explore a range of therapeutic doses for the combination of OCA and bezafibrate. Study 747-213 is for patients outside of the United States. Study 747-214 is for patients … ContinuedFDA issued a Complete Response Letter to Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) marketing application seeking approval for obeticholic acid (OCA) for pre-cirrhotic fibrosis due to NASH.Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. Shares of Intercept Pharmaceuticals Inc. (ICPT) were set to soar Tuesday, after the biopharmaceutical company announced an agreement to be acquired by Italy's Alfasigma S.p.A in a deal that values ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Nov 8, 2023 · BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ... MORRISTOWN, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …Shares of Intercept Pharmaceuticals, Inc. ICPT gained 12.4% in the last six months compared with the industry’s growth of 0.3%. Investors are upbeat on the performance of lead drug Ocaliva and ...Sep 30, 2022 · Follow. MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel ...

Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops, and commercializes treatments for non-viral, progressive liver diseases. It develops products using proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist ...

Jun 23, 2023 · FDA issued a Complete Response Letter to Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) marketing application seeking approval for obeticholic acid (OCA) for pre-cirrhotic fibrosis due to NASH ...

May 5, 2022 · MORRISTOWN, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced it has entered into an agreement to sell to Advanz Pharma, a pharmaceutical company ... MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced a summary of the actions it has taken to improve its capital …MORRISTOWN, N.J., April 13, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …২৬ সেপ, ২০২৩ ... Intercept Pharmaceuticals' acquisition by Alfasigma comes three ... © 2023 Breaking Media, Inc. All rights reserved. Registration or use ...MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...Intercept Pharmaceuticals (NASDAQ:ICPT) is a biopharmaceutical company focused on developing and marketing innovative treatments for progressive liver diseases that are not caused by viruses.Inside Intercept Pharmaceuticals, Inc.'s 10-K Annual Report: Financial - Expense Highlight. Net cash used in operating activities of $198.2 million for continuing operations during the year ended December 31, 2020 was primarily a result of our $273.4 million net loss from continuing operations and a net decrease in operating assets and …Clinical Review Report: Obeticholic Acid (Ocaliva): (Intercept Pharmaceuticals Canada, Inc.) [Internet]. Review. Ottawa (ON): Canadian Agency for Drugs and ...

Our employees are enthusiastic and hard-working individuals who embody our values. Intercept is a biopharmaceutical company working to make a difference in the lives of people living with rare and serious liver diseases. If you are solutions-focused, strive for excellence and want to make an incredible impact on the lives of people living with ... MORRISTOWN, N.J. , July 26, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the …Oct 11, 2023 · The information agent for the tender offer is Georgeson LLC. Intercept stockholders who need additional copies of the Offer to Purchase, Letter of Transmittal or related materials or who have ... BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of ...Instagram:https://instagram. nyse bmybest rated stock appnfl doctor30 day t bill rates Alfasigma S.p.A. today announced that its wholly-owned subsidiary, Interstellar Acquisition Inc., a Delaware corporation, has commenced a cash tender offer to purchase all of the outstanding ... when to buy bonds vs stockshesm stock dividend Director. Keith Gottesdiener, M.D. has served as a member of our Board of Directors since July 2016. Since July 2020, Dr. Gottesdiener has served as the President and Chief Executive Officer and as a director of Prime Medicine, Inc., a biopharmaceutical company based in Cambridge, Massachusetts. Prior to that, from October 2011 until March 2020 ...Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. BOLOGNA, Italy and MORRISTOWN, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alfasigma S.p.A. (“Alfasigma”) and Intercept ... cignaplus savings program What is PBC? Primary Biliary Cholangitis (PBC) is a progressive autoimmune disease that damages the bile ducts in the liver. PBC is a leading cause of liver transplant for women. Learn more Ally, living with PBC Patient Resources We are committed to helping patients access disease education, treatment support and financial options. Read more Director. Mark Pruzanski, M.D. is one of our co-founders and has served as a member of our Board of Directors since inception in 2002. Dr. Pruzanski served as Intercept’s President and Chief Executive Officer until 2021. Dr. Pruzanski has over 20 years of experience in life sciences company management, venture capital and strategic consulting. As pet owners, we want to keep our furry friends safe and secure. Invisible Fence Inc. has been providing pet owners with innovative solutions to keep their pets out of harm’s way for over 40 years. With their advanced technology, Invisible...